Cure and survival of sporadic medullary thyroid carcinoma following systematic preoperative calcitonin screening

[1]  C. Mian,et al.  Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience , 2018, World Journal of Surgery.

[2]  Jin Hwa Kim,et al.  Clinicopathological Significance and Prognosis of Medullary Thyroid Microcarcinoma: A Meta-analysis , 2017, World Journal of Surgery.

[3]  S. Roman,et al.  Surgical management of medullary thyroid carcinoma , 2017, Updates in Surgery.

[4]  David F Schneider,et al.  Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years , 2017, Surgery.

[5]  H. Dralle,et al.  Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. , 2016, European journal of endocrinology.

[6]  Jeong Hyun Lee,et al.  Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma , 2016, Journal of surgical oncology.

[7]  정종주,et al.  Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 years , 2016 .

[8]  Douglas B. Evans,et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.

[9]  T. Samulski,et al.  The variable pathologic presentations of medullary and micro-medullary thyroid carcinoma: an institutional experience. , 2014, Pathology, research and practice.

[10]  S. Roman,et al.  Medullary thyroid microcarcinoma , 2012, Cancer.

[11]  M. Schlumberger,et al.  Medullary thyroid carcinoma. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[12]  S. Roman,et al.  Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. , 2008, The Journal of clinical endocrinology and metabolism.

[13]  C. Bieglmayer,et al.  Medullary thyroid microcarcinoma recommendations for treatment - a single-center experience. , 2007, Surgery.

[14]  A. Pinchera,et al.  RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. , 2007, The Journal of clinical endocrinology and metabolism.

[15]  E. Kebebew,et al.  Extent of disease and practice patterns for medullary thyroid cancer. , 2005, Journal of the American College of Surgeons.

[16]  F. Sebag,et al.  Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  Erik G. Cohen,et al.  Medullary thyroid carcinoma , 2004, Acta oto-laryngologica.

[18]  A. Pinchera,et al.  Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. , 2004, The Journal of clinical endocrinology and metabolism.

[19]  J. Hahm,et al.  Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. , 2001, Thyroid : official journal of the American Thyroid Association.

[20]  Q. Duh,et al.  Medullary thyroid carcinoma , 2000, Cancer.

[21]  O. Haas,et al.  C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin. , 1998, The American journal of surgical pathology.

[22]  M. Schlumberger,et al.  Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients , 1998 .

[23]  M. Schlumberger,et al.  Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. , 1998, Clinical endocrinology.